Free Trial

Burning Rock Biotech (BNR) Competitors

Burning Rock Biotech logo
$3.38 +0.15 (+4.49%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BNR vs. XGN, CORBF, EUDA, NAKA, KDLY, QIPT, ATPC, SERA, OPGN, and PIII

Should you be buying Burning Rock Biotech stock or one of its competitors? The main competitors of Burning Rock Biotech include Exagen (XGN), Global Cord Blood (CORBF), EUDA Health (EUDA), KindlyMD (NAKA), Kindly MD (KDLY), Quipt Home Medical (QIPT), Agape ATP (ATPC), Sera Prognostics (SERA), OpGen (OPGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

Burning Rock Biotech vs. Its Competitors

Burning Rock Biotech (NASDAQ:BNR) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

In the previous week, Exagen had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for Exagen and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company Overall Sentiment
Burning Rock Biotech Neutral
Exagen Neutral

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exagen has lower revenue, but higher earnings than Burning Rock Biotech. Exagen is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$523.28M0.07-$47.49M-$1.89-1.79
Exagen$55.64M2.58-$15.11M-$0.84-8.02

Exagen has a consensus target price of $7.50, suggesting a potential upside of 11.34%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Burning Rock Biotech has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.

Exagen has a net margin of -27.34% compared to Burning Rock Biotech's net margin of -45.41%. Burning Rock Biotech's return on equity of -38.33% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-45.41% -38.33% -25.34%
Exagen -27.34%-133.69%-34.87%

Summary

Exagen beats Burning Rock Biotech on 10 of the 15 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNR vs. The Competition

MetricBurning Rock BiotechTechnology Services IndustryBusiness SectorNASDAQ Exchange
Market Cap$36.32M$2.40B$13.04B$9.01B
Dividend YieldN/A1.34%2.58%4.11%
P/E Ratio-1.7931.4228.5920.07
Price / Sales0.0736.5339.59109.13
Price / CashN/A39.2125.1456.90
Price / Book0.465.826.255.70
Net Income-$47.49M$32.32M$187.50M$248.47M
7 Day Performance-1.03%4.77%2.84%2.92%
1 Month Performance13.26%8.28%4.82%5.77%
1 Year Performance-44.76%51.43%34.94%21.39%

Burning Rock Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNR
Burning Rock Biotech
1.0119 of 5 stars
$3.38
+4.5%
N/A-47.8%$36.32M$523.28M-1.791,390
XGN
Exagen
2.8081 of 5 stars
$6.97
-3.6%
$7.50
+7.6%
+291.6%$154M$55.64M-8.30220
CORBF
Global Cord Blood
N/A$1.18
-6.3%
N/A+45.0%$143.43M$196.12M0.001,200Gap Down
EUDA
EUDA Health
0.7706 of 5 stars
$3.58
-3.8%
N/A-5.6%$138.21M$4.01M0.002Gap Up
NAKA
KindlyMD
N/A$16.30
+14.6%
N/AN/A$85.74M$2.72M0.00N/APositive News
KDLY
Kindly MD
N/A$14.22
+2.0%
N/A+518.6%$85.63M$2.47M-18.47N/APositive News
QIPT
Quipt Home Medical
2.3772 of 5 stars
$1.93
+1.0%
$2.85
+47.7%
-42.9%$82.98M$245.91M-9.191,200
ATPC
Agape ATP
0.064 of 5 stars
$1.37
-12.7%
N/A-65.5%$78.51M$1.32M-2.2840Positive News
Gap Down
SERA
Sera Prognostics
1.4474 of 5 stars
$1.87
-2.6%
N/A-56.2%$72.33M$80K-1.99120Positive News
Gap Down
OPGN
OpGen
N/A$4.88
flat
N/A+80.5%$49.13M$2.67M0.00100Upcoming Earnings
Gap Down
PIII
P3 Health Partners
2.9111 of 5 stars
$6.17
-1.3%
$16.25
+163.4%
-72.4%$44.92M$1.50B-0.13500News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:BNR) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners